CD274 and neoplasm: As described earlier, programmed cell death receptor ligand 1 (PD-L1) has been reported to be packaged into the sEVs of tumor cells, and PD-L1 in sEVs enables cancer cells to evade anti-tumor immunity by inhibiting T cell activation (102).